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a  b  s  t  r  a  c  t
3-Nitrobenzanthrone  (3-NBA)  is  a highly  mutagenic  compound  and possible  human  carcinogen  found
in  diesel  exhaust.  3-NBA  forms  bulky  DNA  adducts  following  metabolic  activation  and  induces  predomi-
nantly  G:C  > T:A  transversions  in a variety  of  experimental  systems.  Here  we  investigated  the  inﬂuence  of
nucleotide  excision  repair  (NER)  on  3-NBA-induced  mutagenesis  of  the  human  tumour  suppressor  gene
TP53 and  the  reporter  gene  lacZ.  To  this  end  we  utilised  Xpa  -knockout  (Xpa-Null)  human  TP53  knock-in
(Hupki)  embryo  ﬁbroblasts  (HUFs).  As  Xpa is essential  for NER  of  bulky  DNA  adducts,  we hypothesized
that DNA  adducts  induced  by  3-NBA  would  persist  in  the genomes  of Xpa-Null  cells and  lead  to an
increased  frequency  of  mutation.  The  HUF  immortalisation  assay  was  used  to  select  for  cells harbouring
TP53  mutations  following  mutagen  exposure.  We  found  that  Xpa-Null  Hupki  mice  and  HUFs  were  more
sensitive  to  3-NBA  treatment  than  their  wild-type  (Xpa-WT)  counterparts.  However,  following  3-NBA
treatment  and  immortalisation,  a similar  frequency  of TP53-mutant  clones  arose  from  Xpa-WT  and  Xpa-
Null HUF  cultures.  In  cells  from  both  Xpa  genotypes  G:C  > T:A transversion  was  the  predominant  TP53
mutation  type  and mutations  exhibited  bias  towards  the  non-transcribed  strand.  Thirty-two  percent  of
3-NBA-induced  TP53  mutations  occurred  at CpG  sites,  all of which  are  hotspots  for mutation  in  smokers’
lung cancer  (codons  157, 158,  175,  245,  248,  273, 282).  We  also  examined  3-NBA-induced  mutagenesis
of  an  integrated  lacZ  reporter  gene  in  HUFs,  where  we  again  observed  a similar  mutant  frequency  in
Xpa-WT  and  Xpa-Null  cells.  Our  ﬁndings  suggest  that  3-NBA-DNA  adducts  may  evade  removal  by global
genomic  NER;  the  persistence  of  3-NBA  adducts  in  DNA  may  be an important  factor  in its mutagenicity.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Lung cancer is the most common malignant disease world-
ide. While tobacco smoking is the predominant cause of lung
ancer, vehicular exhaust and ambient air pollution are also impli-
ated [1,2]. In Great Britain diesel engine exhaust is the sixth most
mportant occupational carcinogen [3]. Moreover, two recent epi-
emiological studies of miners provide strong evidence for a link
etween diesel exposure and lung cancer risk, ﬁnding a 3-fold
ncreased risk for lung cancer overall and a 5-fold increased risk
∗ Corresponding author at: Analytical and Environmental Sciences Division, MRC-
HE Centre for Environment & Health, King’s College London, Franklin-Wilkins
uilding, 150 Stamford Street, London SE1 9NH, United Kingdom.
E-mail address: jill.kucab@kcl.ac.uk (J.E. Kucab).
ttp://dx.doi.org/10.1016/j.dnarep.2015.11.004
568-7864/© 2015 The Authors. Published by Elsevier B.V. This is an open access article ufor miners most heavily exposed to diesel exhaust [4,5]. Subse-
quently, the International Agency for Research on Cancer (IARC)
has classiﬁed diesel engine exhaust as Group 1 human carcinogen
[2].
The extremely potent mutagen 3-nitrobenzanthrone (3-nitro-
7H-benz[de]anthracen-7-one, 3-NBA) can be found on the surface
of ambient air particulate matter and diesel exhaust particles [6]
and has been classiﬁed as a possible human carcinogen (Group
2B) by IARC [2]. Human exposure to 3-NBA has been demon-
strated in workers occupationally exposed to diesel emissions
[7] and intratracheal instillation of 3-NBA induces squamous cell
carcinoma in rat lung [8]. Premutagenic bulky DNA adducts gener-
ated by 3-NBA are critical for its high mutagenic potency [9,10].
In order to form DNA adducts, 3-NBA requires metabolic acti-
vation via reduction of its nitro group [11,12]. The predominant
DNA adducts detected in vitro and in vivo after treatment with
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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-NBA are at guanine residues, i.e. 2-(2′-deoxyguanosin-N2-yl)-3-
minobenzanthrone (dG-N2-3-ABA) and N-(2′-deoxyguanosin-8-
l)-3-aminobenzanthrone (dG-C8-N-3-ABA) (see Supplementary
ig. 1) [12,13]. The mutagenic potency of 3-NBA has been shown
n a variety of experimental systems [14,15]. 3-NBA-DNA adducts
referentially induce G:C > T:A transversions in vitro and in vivo in
eporter genes [9,10,16].
3-NBA was also shown to induce G:C > T:A transversions in the
umour suppressor gene TP53 in immortalized embryonic ﬁbrob-
asts derived from the human TP53 knock-in (Hupki) mouse, which
arbours exons 4–9 of human TP53 in place of the corresponding
ouse exons [17] [18]. TP53, which encodes the protein p53, is a
ey cancer gene and is somatically mutated in approximately half
f human cancers [19,20]. Over 28,000 TP53 mutations detected
n human tumours have been catalogued in the IARC TP53 muta-
ion database [21]. Some of these mutations in TP53 bear hallmarks
f carcinogen exposure and can offer clues to tumour aetiology
22]. Carcinogen-induced TP53 mutagenesis can be studied in vitro
sing the Hupki mouse embryo ﬁbroblast (HUF) immortalization
ssay (HIMA) [23,24]. HUFs that acquire TP53 mutations follow-
ng mutagen treatment can bypass culture-induced senescence and
ecome immortalised clones, in which mutations can be identiﬁed
y DNA sequencing. The HIMA allows a direct comparison between
utations induced in vitro in a human cancer gene (i.e. TP53) and
utations that occur in tumours of populations exposed to a par-
icular carcinogen.
Bulky DNA adducts, such as those formed by polycyclic aromatic
ydrocarbons (PAHs), can be removed from the genome by the
ucleotide excision repair (NER) pathway [25,26]. We  developed
 Hupki mouse strain harbouring a knockout allele for a critical
ER component, Xpa (xeroderma pigmentosum complementation
roup A) (Hupki;  Xpa+/−), with the aim of increasing TP53 muta-
ion frequency in the HIMA [27]. Xpa is critical for both global
enomic NER (GG-NER) and transcription-coupled NER (TC-NER),
hus Xpa−/− (Xpa-Null) HUFs derived from Hupki;  Xpa+/− mice are
ompletely deﬁcient in NER and incapable of removing bulky DNA
dducts from their genome [25]. We  recently showed that Xpa-
ull HUFs, compared with Xpa+/+ (Xpa-WT) HUFs, are extremely
ensitive to the PAH benzo[a]pyrene (BaP) and exhibit increased
P53 mutagenesis on the transcribed strand when treated with
he reactive intermediate of BaP, benzo[a]pyrene-7,8-diol-9,10-
poxide (BPDE) [27].
In the present study, we  examined the impact of NER-deﬁciency
n 3-NBA-induced adduct formation (in vitro and in vivo) and
P53 mutagenesis in HUFs. We  hypothesized that 3-NBA-induced
NA adducts would persist in the genomes of Xpa-Null Hupki
ice and HUFs, and that these persistent adducts would lead to
ncreased mutation induction during replication of adducted DNA
28,29]. In addition to TP53 mutagenesis, we examined 3-NBA-
nduced mutations in a lacZ reporter gene in Xpa-WT and Xpa-Null
UFs derived from Hupki;  Xpa +/− mice, as the pUR288 plasmid
ocus has also been integrated into this strain [30]. The pUR288
lasmid can be extracted from the genomic DNA of mutagen-
reated cells following 1–3 days of proliferation and lacZ mutations
dentiﬁed by selection in Escherichia coli host cells [31]. In this
ay, the frequency of mutations induced by carcinogen treat-
ent may  be studied in a short-term reporter gene assay (in a
anner that is not dependent on selection within HUFs) in par-
llel to TP53. As the HIMA takes several months to complete,
e aimed to evaluate whether the mutagenic activity of a car-
inogen (i.e. 3-NBA) could be rapidly assessed in HUFs using
he lacZ system. This would potentially aid in the optimisation
f experimental treatment conditions prior to initiation of the
IMA.ir 39 (2016) 21–33
2. Materials and methods
2.1. Carcinogen information
3-NBA was  synthesised as described previously [32]. For in vivo
treatments 3-NBA was  dissolved in tricaprylin at a concentration of
0.5 mg/mL. For treatment of cells in culture, 3-NBA was dissolved
in DMSO to a stock concentration of 4 mM and stored at −20 ◦C.
2.2. Description of mouse strain and details of genotyping
A mouse strain homozygous for the Hupki allele (a knock-in
allele harbouring exons 4–9 of the human TP53 gene) and het-
erozygous for an Xpa-knockout allele was generated as described
previously [27]. This strain is on a mixed 129/Sv and C57Bl/6 back-
ground and also harbours the pUR288 plasmid (containing the
bacterial lacZ mutation marker gene) [30,33]. The pUR288 plas-
mid  is chromosomally integrated in ∼20 tandem copies per haploid
genome. More information can be found at the European Mouse
Mutant Archive (EMMA; www.infrafrontier.eu) where this strain
has been deposited (EMMA  ID EM:08137). Hupki+/+; Xpa+/−; lacZ +
mice were bred to produce Xpa+/+ (Xpa-WT) and Xpa−/− (Xpa-Null)
mice and embryos for experiments. Genotyping for Hupki,  Xpa and
lacZ was performed as described previously [27] using the primers
and PCR conditions detailed in Supplementary Table 1. Note that
genotyping for lacZ cannot differentiate between genomes that are
haploid or diploid for pUR288 but this does affect the outcome of
the lacZ mutation assay.
2.3. In-vivo 3-NBA treatment
All animal experiments were carried out under license accord-
ing to protocols approved by the Home Ofﬁce under the Animals
(Scientiﬁc Procedures) Act (1986) after approval by the institu-
tional ethics committee. Groups of female Xpa-WT and Xpa-Null
Hupki mice (∼3 months old; 20–25 g; n = 3/group) were treated
with 3-NBA following a treatment protocol published previously
[34]. In Groups 1–3 mice were treated with 2 mg/kg bw 3-NBA
by intraperitoneal (i.p.) injection. Groups 1 and 2 received a single
dose and were sacriﬁced 1 day and 5 days after the last adminis-
tration, respectively. Group 3 was dosed once daily for 5 days and
sacriﬁced 24 h after the last injection. Groups 4 and 5 were treated
i.p. with 0.2 mg/kg bw 3-NBA. Whereas Group 4 was treated with
a single dose and sacriﬁced 24 h later, Group 5 was  dosed once
daily for 5 days and sacriﬁced 24 h after the last administration.
Matched control mice (n = 3) to Groups 3 and 5 received tricaprylin
only. Liver, lung, small intestine, spleen, colon and kidney tissues
were removed, snap frozen in liquid N2, and stored at −80 ◦C until
analysis.
2.4. DNA adduct analysis by 32P-postlabelling
Genomic DNA was  isolated from cells or tissue by a standard
phenol/chloroform extraction method and stored at −20 ◦C. DNA
adducts were measured in each DNA sample using the butanol
enrichment version of the 32P-postlabelling method as described
previously [32,35] with minor modiﬁcations. Brieﬂy, DNA  sam-
ples (4 g) were digested with micrococcal nuclease (120 mU;
Sigma, #N3755) and calf spleen phosphodiesterase (40 mU;  Cal-
biochem, #524711), enriched and labelled with 50 Ci [-32P]ATP
(Hartmann Analytic #HP601ND) as reported. 3-NBA-derived DNA
adducts were identiﬁed as reported [11–13].2.5. Isolation and culture of primary HUFs
Xpa-WT and Xpa-Null Hupki mouse embryonic ﬁbroblasts
(HUFs) were isolated from day 13.5 embryos of intercrosses of
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upki+/+; Xpa+/−; lacZ+ mice according to a standard procedure, as
escribed previously [27]. Isolated HUFs were cultured to 80–90%
onﬂuence for 2–3 days in growth medium (Dulbecco’s modiﬁed
edium (Invitrogen #31966-021) supplemented with 10% fetal
ovine serum (Invitrogen #26140-079) and 100 U/mL penicillin
nd streptomycin (Invitrogen #15140-130) at 37 ◦C/5% CO2/3% O2
efore preparing frozen stocks (passage 0) and genotyping.
Cells were cultured in growth medium at 37 ◦C/5% CO2 in either
0% or 3% O2, adjusted using an incubator ﬁtted with an oxygen
ensor and a nitrogen source. Manipulations conducted outside
he incubator were performed at 20% O2. For passaging cells were
etached with 0.05% trypsin-EDTA (Invitrogen #25300-062), sus-
ended in growth media and reseeded at the desired dilution or
ell number.
.6. Cell survival assay
Cell survival was assessed using a crystal violet staining assay as
escribed previously [27]. Xpa-WT or Xpa-Null HUFs were seeded
nto 96-well plates at 2.5–5.0 × 103 cells/well and treated the fol-
owing day with 3-NBA diluted in growth medium to a highest
nal concentration of 4 M (0.1% DMSO). Cells were treated at
7 ◦C/5% CO2/3% O2 in 5 replicate wells per concentration of 3-NBA
r DMSO (control). Following 24 or 48 h of treatment, cells were
insed with PBS, stained for 15 min  with 0.1% (w/v) crystal violet
Sigma #C3886) in 10% ethanol, washed again with PBS to remove
xcess dye and then allowed to air-dry. To quantify the crystal vio-
et retained by surviving cells, 100 L of 50% ethanol was  added per
ell to solubilise the dye and the absorbance at 595 nm was deter-
ined using a plate reader. Data are presented as the percentage
f A595nm in 3-NBA treated cells relative to that of control cells and
re representative of at least three independent experiments.
.7. 3-NBA treatment of HUFs for DNA adduct analysis
Xpa-WT and Xpa-Null HUFs were cultured and treated at
7 ◦C/5% CO2 in either 3% or 20% O2. HUFs (passage 1, ≤ 7 days in cul-
ure) were seeded at 1.0–1.5 × 106 cells/75-cm2 ﬂask and treated
he following day for 48 h. 3-NBA was diluted in growth medium to
 ﬁnal concentration of 0.1, 0.5, 1.0 or 2.0 M (0.1% DMSO) and cells
ere treated in duplicate ﬂasks per condition. Following treatment
ells were trypsinised, pelleted and stored at −20 ◦C until further
nalysis.
.8. Western blotting
Treated cells were lysed with 62.5 mM Tris–HCl pH 6.8, 500 mM
DTA pH 8.0, 2% sodium dodecyl sulphate (SDS) and 10% glyc-
rol, supplemented with fresh protease inhibitors (78425; Thermo
isher, UK). The expression of p53, phospho-p53 (S15), p21 and
apdh in the lysates was assessed by SDS-PAGE and Western
lotting as reported previously [36] using the following pri-
ary antibodies: anti-p53 (NCL-p53-CM5, Leica Microsystems, UK;
:1,000), anti-phospho-p53 (#9284, Cell Signaling Technology, UK;
:1,000); anti-p21 (#556431, BD Bioscience, UK; 1:2,000); and
apdh (#MAB374, Millipore, UK; 1:25,000).
.9. Hupki mouse embryo ﬁbroblast immortalisation assay
HIMA)
Primary HUFs treated with 3-NBA were immortalised essen-
ially as described previously [27,37]. Frozen stocks (passage 0) of
pa-WT and Xpa-Null primary HUFs were thawed and expanded
n 175-cm2 ﬂasks at 37 ◦C/5% CO2/3% O2 for 72 h until 80–90%
onﬂuent. Cells were trypsinised, counted and seeded at 2.0 × 105ir 39 (2016) 21–33 23
cells/well into 6-well Corning CellBind® plates. Cells were treated
the following day with 1 M 3-NBA for 48 h (36 cultures, each Xpa
genotype) or 2 × 48 h (24 cultures, each Xpa genotype). For cultures
receiving 2 treatments, ∼300,000 cells from each culture (Xpa-WT
and Xpa-Null) were reseeded following the ﬁrst 48 h treatment
with 3-NBA and then retreated the following day for a further 48 h.
Additionally, a set of HUF cultures (54 cultures, each Xpa genotype)
were treated with 0.1% DMSO in parallel [27].
Following treatment, as cultures approached conﬂuence, HUFs
were subcultured on 6-well Corning CellBind® plates at a dilution of
1:2–1:4. At Day 11 (post-thaw), all cultures were transferred to 20%
O2 to select for senescence bypass. Cultures were serially passaged
at dilutions of 1:2–1:4 until senescence/crisis (ceasing of cell divi-
sion and enlarged morphology); during crisis cells received fresh
media every 3 days. Serial passaging was  resumed once regions
of dividing cells emerged (immortalised clones). Cultures contain-
ing clones were split at dilutions of at least 1:2–1:4 for several
passages, followed by further passaging at dilutions up to 1:20.
Cultures were expanded to larger ﬂasks (25-, 75-cm2) once they
appeared homogenous and achieved a doubling rate of ≤ 48 h;
frozen stocks were prepared and a portion of cells was pelleted
for DNA extraction (≥ passage 12; 8–16 weeks).
2.10. TP53 mutation analysis
DNA for TP53 mutations analysis was prepared as described
recently [27]. Human TP53-speciﬁc primers (exon 4 to exon 9,
including introns, and cycling conditions are described in Supple-
mentary Table 2). PCR ampliﬁcation products were submitted to
Beckman Coulter Genomics (Takeley, UK) for Sanger dideoxy ﬂu-
orescent sequencing using the sequencing primers indicated in
Supplementary Table 2. Sequences were assessed for the presence
of TP53 mutations as described [27]. Variations (e.g. single base sub-
stitutions, deletions) were assessed using the mutation validation
tool available at the IARC TP53 mutation database (http://www-
p53.iarc.fr/MutationValidationCriteria.asp) and could be classiﬁed
as either homo-/hemi-zygous or heterozygous. Mutations were
conﬁrmed by sequencing DNA from an independent sample of cells
from the same clone.
2.11. lacZ mutation assay
Xpa-WT and Xpa-Null primary HUFs (passage 0) carrying the
lacZ reporter gene were thawed and expanded at 37 ◦C/5% CO2/3%
O2 for 72 h. Cells (1.0–1.5 × 106) were seeded into 75-cm2 ﬂasks
(5 ﬂasks per treatment). The following day cells were treated
with 3-NBA (0.1, 0.5, 1.0 or 2.0 M;  cytotoxic and sub-cytotoxic
concentrations) or solvent control (0.1% DMSO) for 48 h. After
treatment, cells from each ﬂask were trypsinised, counted and
reseeded at 1.75 × 106 cells into 175-cm2 ﬂasks to allow cells to
proliferate and ﬁx mutations. After 96 h, when control cultures
were ∼90% conﬂuent, cells were trypsinised, pelleted and stored
at −20 ◦C until DNA isolation. DNA was isolated from cells by stan-
dard phenol/chloroform extraction. pUR288 (lacZ) plasmid rescue
and mutant frequency determination were performed as described
previously [38–40]. Brieﬂy, 10–30 g of DNA were digested with
HindIII and then incubated with magnetic beads coated with
lacI fusion protein. Plasmids were eluted from the beads using
isopropyl--D-thiogalactopyranoside (IPTG), circularised at the
cohesive HindIII sites using T4 DNA ligase and then electropo-
rated into E. coli deﬁcient in -galactosidase (lacZ−) and galactose
epimerase (galE−). One thousandth of the transformed bacteria was
plated on nonselective, titre plates (containing X-Gal (5- bromo-4-
chloro-3-indolyl--D-galactopyranoside)) and the remainder was
plated onto selective plates (containing the lactose analog P-Gal
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Fig. 1. DNA adduct formation in Xpa-WT and Xpa-Null Hupki mice treated with 3-NBA. Mice were treated with 3-NBA (2 or 0.2 mg/kg bw)  either once (A) and (C) or once
a  day for 5 days (B) and (D). DNA adduct levels (RAL, relative adduct labelling) in the indicated tissues were assessed by 32P-postlabelling. See Supplementary Fig. 2 for
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cepresentative autoradiograms showing the adduct proﬁles in examined tissues. Va
ndependent 32P-postlabelling analyses. ND = not detected; †  = not determined due t
pa-WT and Xpa-Null mice, was performed using the Student’s t -test; * P < 0.05.
phenyl--D galactosidase)). Mutant frequencies were calculated
s the ratio between the number of mutant colonies on the selec-
ive plate to the total number of colonies on the titre plate (times
he dilution factor of 1,000).
. Results
.1. DNA adduct formation by 3-NBA in Xpa-WT and Xpa-Null
upki miceThe effect of NER deﬁciency on 3-NBA-induced DNA adduct
ormation in vivo was assessed by 32P-postlabelling (Fig. 1). The
NA adduct pattern induced by 3-NBA (see Supplementary Fig. 2)
onsisted of up to four adduct spots. These were identiﬁed pre-epresent means ± SD from 3 animals, and each DNA sample was measured by two
th of Xpa-Null animals. Statistical analysis, comparing adduct levels in tissues from
viously [11–13] as deoxyadenosine (adduct spots 1 and 2) and
deoxyguanosine adducts (adduct spots 3 and 4), of which three
have been structurally characterised as 2-(2′-deoxyadenosin-N6
aminobenzanthrone (dA-N6-3-ABA; spot 1), 2-(2′-deoxyguanosin-
N2-yl)-3-aminobenzanthrone (dG-N2-3-ABA; spot 3) and N-
(2′-deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-3-ABA;
spot 4). The structures of these adducts are shown in Supplemen-
tary Fig. 1.
One day after a single administration of 2 mg/kg bw 3-NBA, Xpa-
Null mice had a 1.6-fold higher level of DNA adducts in the lung
compared to Xpa-WT animals but similar DNA adduct levels in the
liver, small intestine and colon (Fig. 1A). No adducts were detected
in spleen or kidney. The highest levels of adducts were detected in
liver (51 ± 17 [Xpa-WT] versus 36 ± 9 adducts per 108 nt [Xpa-Null])
A Repair 39 (2016) 21–33 25
a
[
X
b
e
t
e
i
(
a
l
D
a
W
i
d
a
D
l
f
l
B
0
i
t
t
a
W
r
e
d
3
c
t
c
e
O
o
t
T
D
g
a
h
t
m
3
X
(
N
d
h
(
f
3
a
X
48 hr
0
100
200
300
400
500
600
R
A
L 
pe
r 
10
8
n
u
cl
eo
tid
es
20% O2
3% O2
1 µM 3-NBA
F=1.9 *
Fig. 2. 3-NBA-induced DNA adduct formation in HUFs cultured at 20% or 3% O2.
Xpa-WT HUFs cultured in 20% or 3% O2 were treated for 48 h with 1 M 3-NBA. DNA
adduct formation (RAL, relative adduct labelling) was assessed by 32P-postlabelling.
Values represent means ± SD of two biological replicates where each DNA sample
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nd colon (55 ± 13 [Xpa-WT] versus 61 ± 23 adducts per 108 nt
Xpa-Null]). While 3-NBA was well tolerated by Xpa-WT mice, all
pa-Null mice died within 2–3 days of 3-NBA treatment (2 mg/kg
w) (Fig. 1B and Supplementary Fig. 3). 3-NBA-DNA adduct lev-
ls persisted in the tissues of Xpa-WT mice 5 days after a single
reatment (Supplementary Fig. 3). Further, 3-NBA-DNA adduct lev-
ls increased nearly 6-fold in the liver and ∼2-fold in the small
ntestine of mice that were treated daily for 5 consecutive days
Fig. 1B).
As Xpa-Null mice were highly sensitive to treatment with 3-NBA
t 2 mg/kg bw, animals were subsequently treated with a 10-fold
ower dose (0.2 mg/kg bw)  in a follow-up experiment (Fig. 1C and
). In mice treated once with 0.2 mg/kg bw 3-NBA, 3-NBA-DNA
dducts were detectable in the lungs of Xpa-Null mice but not Xpa-
T mice; no signiﬁcant difference between DNA adduct formation
n Xpa-WT and Xpa-Null animals was found in other organs with
etectable levels of 3-NBA-DNA adducts (i.e. liver, small intestine,
nd colon). Following a single treatment with 0.2 mg/kg bw 3-NBA,
NA adduct levels in the lung, small intestine and colon were at
east 2-fold lower, or undetectable, (Fig. 1C) compared with tissues
rom mice that received 2 mg/kg bw (Fig. 1A). In contrast, adduct
evels in the liver were similar after low or high dose treatment.
oth Xpa-WT and Xpa-Null mice survived 5 daily treatments of
.2 mg/kg bw 3-NBA. Again 3-NBA-DNA adducts were detectable
n the lungs of Xpa-Null mice but not in Xpa-WT mice, indicating
hat 3-NBA-DNA adducts were repaired by NER. In the other two
issues (liver and small intestine) assessed from Group 5 animals,
 trend for higher DNA adduct levels in Xpa-Null mice than in Xpa-
T mice was found (Fig. 1D), but the observed difference did not
each statistical signiﬁcance. Interestingly, adduct levels in the liv-
rs of both genotypes from Group 5 mice were lower than those
etected for Group 4 animals (Fig. 1C).
.2. 3-NBA-induced DNA adduct formation in Xpa-WT HUFs
ultured in 3% or 20% O2
We  then went on to examine DNA adduct formation in HUFs
reated with 3-NBA. Previously, we showed that when HUFs were
ultured in physiological O2 (3%) their replicative potential was
nhanced [27]. This suggested that cells could be cultured in 3%
2 before and during mutagen treatment to increase the number
f cells available for experiments. Cells would then be transferred
o 20% O2 to select for mutated cells capable of senescence bypass.
he impact of oxygen on 3-NBA metabolism and 3-NBA-induced
NA damage is unknown. Thus, we treated primary Xpa-WT HUFs
rown in 3% or 20% O2 with 1 M 3-NBA for 48 h to assess DNA
dduct formation. We  found that DNA adduct levels were 2-fold
igher in HUFs treated with 3-NBA in 3% O2 compared with cells
reated in 20% O2 (Fig. 2). Therefore, all subsequent 3-NBA treat-
ents of HUFs in this study were performed in 3% O2.
.3. DNA adduct formation and survival of 3-NBA-treated
pa-WT and Xpa-Null HUFs
Xpa-WT and Xpa-Null HUFs were compared for their sensitivity
i.e. cell survival) to 3-NBA after 24 or 48 h treatment (Fig. 3A). Xpa-
ull HUFs were more sensitive to 3-NBA treatment; however, the
ecrease in cell survival was more pronounced after 48 h. After 24-
 treatment with 1 M 3-NBA, 80% of Xpa-Null cells had survived
similar for Xpa-WT), whereas after 48-h treatment, the surviving
raction was ∼30% of control (∼70% for Xpa-WT). At higher doses of
-NBA (2–4 M),  most Xpa-Null cells were dead after 48 h, whereas
t least 40% of Xpa-WT cells had survived.
Next, DNA adduct formation induced by 3-NBA was assessed in
pa-WT and Xpa-Null HUFs. Cells were treated with 0.1–2.0 M ofwas  measured by two  independent P-postlabelling analyses. Statistical analy-
sis,  comparing DNA adduct formation at 20% and 3% O2,  was performed using the
Student’s t -test; * P < 0.05.
3-NBA for 48 h (Fig. 3B). Although proﬁcient in NER, Xpa-WT HUFs
accumulated similar levels of DNA adducts (up to ∼300 adducts
per 108 nt) to Xpa-Null HUFs after treatment with 0.1–1.0 M 3-
NBA. However, while Xpa-WT HUFs accrued 507 ± 144 adducts per
108 nt after 2 M 3-NBA treatment, Xpa-Null HUFs did not survive
treatment at that concentration. We  concluded from these data that
a 48-h treatment with 1 M 3-NBA induced substantial DNA dam-
age in both Xpa-WT and Xpa-Null HUFs (Xpa-WT: ∼300 adducts
per 108 nt; Xpa-Null: ∼250 adducts per 108 nt) while preserving
a population of viable cells that could proliferate and accumulate
mutations (Xpa-WT: ∼85% survival; Xpa-Null: ∼30% survival). Fur-
ther, as previous HIMAs have often employed repeated treatments
with a mutagen [18,41], we also assessed DNA adduct formation in
HUFs following 2 × 48-h treatments with 1 M 3-NBA (Fig. 3C). In
Xpa-WT HUFs, two treatments with 1 M 3-NBA increased the DNA
adduct level ∼2-fold over the level induced by a single treatment,
whereas in Xpa-Null HUFs DNA adduct levels were nearly the same
after one or two treatments. Cell survival of both Xpa-WT and Xpa-
Null HUFs was  ∼2-fold lower following repeated treatment with
3-NBA than after a single treatment (data not shown).
The adduct patterns induced by 3-NBA (Fig. 3D) consisted of
four adduct spots that were identical to those observed in several
organs of Xpa-WT and Xpa-Null Hupki mice treated with 3-NBA
in vivo (see Supplementary Fig. 2). No DNA adducts were detected
in HUFs treated with solvent (DMSO) only (data not shown).
3.4. Induction of the p53 pathway in Xpa-WT and Xpa-Null HUFs
after 3-NBA treatment
Induction of p53 in 3-NBA-treated Xpa-WT and Xpa-Null HUFs
was assessed by immunoblotting (Supplementary Fig. 4). Expres-
sion of p53, and phosphorylation on serine 15, was highly induced
after treatment of Xpa-Null HUFs with 0.5 and 1.0 M 3-NBA, cou-
pled with a moderate induction of p21, a p53 transcriptional target.
Similar treatment of Xpa-WT cells only slightly induced expres-
sion and phosphorylation of p53, and resulted in a very modest
increase in p21 expression. The highest dose of 3-NBA (2 M)  tested
in Xpa-WT HUFs strongly induced phosphorylation of p53 and
increased p53 expression to a level similar to that observed in Xpa-
Null HUFs treated with 0.5 M 3-NBA. HUFs were also treated with
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Fig. 3. Survival and DNA adduct formation in Xpa-WT and Xpa-Null HUFs treated with 3-NBA. (A) Cells were treated for 24 or 48 h with the indicated doses of 3-NBA
and  survival was  measured using a crystal violet staining assay. Cells treated with 0.1% DMSO only served as control. Mean values are presented as% of control ± SD
of  5 replicate wells and are representative of at least three independent experiments (variation ≤ 15%). (B) and (C) Cells were treated with 3-NBA (as indicated) for
48  h or 2 × 48 h and DNA adduct formation (RAL, relative adduct labelling) was  assessed by 32P-postlabelling. Values represent means ± SD of two biological replicates
where  each DNA sample was measured by two  independent 32P-postlabelling analyses. Due to severe loss of viability, DNA adduct formation was not assessed in Xpa-
Null  cells treated with 2 M 3-NBA (indicated by skull and crossbones). (D) Autoradiographic proﬁles of DNA adducts obtained in 3-NBA-treated HUFs; arrows indicate
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eft-hand corners, were cut off before exposure.
.25 M BaP for comparison. BaP treatment strongly induced p53
xpression and phosphorylation in Xpa-Null cells, whereas the p53
esponse was much weaker in the Xpa-WT cells.
.5. TP53 mutations induced by 3-NBA in Xpa-WT and Xpa-Null
UFs
.5.1. Mutation frequency
We next examined the effect of NER-deﬁciency on 3-NBA-
nduced TP53 mutagenesis using the HIMA. Xpa-WT and Xpa-Null
UFs were treated either 1 × 48 h or 2 × 48 h with 1 M 3-NBA and
hen serially passaged for ≥12 passages (8–16 weeks) until estab-
ished into immortalised clones. Untreated cells were immortalised
n parallel [27]. Mutations in exons 4–9 and adjacent introns of
he human TP53 sequence in immortal HUF clones are shown in
ables 1 and 2.
As described previously [27], TP53 mutations were only detected
n two spontaneously immortalised HUF clones from untreated
ultures of either genotype (3.7%) (Table 1). Following 3-NBA treat-
ent the frequency of TP53-mutated clones increased to 18.3%
n both Xpa-WT and Xpa- Null cultures. A similar frequency of
P53-mutated clones was generated following a single or double
reatment with 3-NBA. A total of 14 TP53 mutations were detected
n 11 immortal clones derived from 3-NBA-treated Xpa-WT cul-
ures (three clones contained two mutations each) and 12 TP53
utations were detected in 11 immortal clones derived from 3-
BA-treated Xpa-Null cultures (1 clone harboured 2 mutations).
reatment with 3-NBA clearly increased the frequency of TP53′-deoxyguanosin-N2-yl)-3-aminobenzanthrone (dG-N2-3-ABA) and spot 4: N-(2′-
e adduct that has not yet been structurally characterised. The origins, in the bottom
mutations over that of untreated cultures, but, interestingly, Xpa-
deﬁciency did not further increase the mutation frequency induced
by 3-NBA.
3.5.2. Mutation pattern and sequence context
All but one of the TP53 mutations (an insertion) were single base
substitutions and occurred at splice sites or in coding sequences,
resulting in an amino acid substitution. No silent or nonsense muta-
tions were found. The predominant mutation type identiﬁed in
clones from 3-NBA-treated cultures was G:C > T:A transversion,
representing 29% of the mutations in Xpa-WT clones and 50% of the
mutations in Xpa-Null clones (Table 1 and Fig. 4). With the excep-
tion of one clone that contained an insertion (XN-3N-151), all of the
remaining mutations found in the 3-NBA-treated Xpa-Null clones
also occurred at G:C base pairs; 25% were G:C > C:G transversions
and 17% were G:C > A:T transitions. G:C > C:G and G:C > A:T base
changes were similarly found in 3-NBA-treated Xpa-WT clones
(∼20% for both mutation types). Guanines at CpG dinucleotides
were often mutational targets in both Xpa-WT and Xpa-Null clones.
Overall, 40% of G:C > A:T transitions and 60% of G:C > T:A transver-
sions occurred at CpG sites (Supplementary Table 3). G:C > G:C
transversions, on the other hand, occurred most frequently in a
sequence context of 5′G-G-C3′.
In contrast to 3-NBA-treated Xpa-Null clones, ∼30% of the muta-
tions in Xpa-WT clones occurred at A:T base pairs. This mutation
type was not found in any 3-NBA-treated Xpa-Null clones. In
untreated control cultures, three of the four TP53 mutations iden-
tiﬁed were A:T > C:G base substitutions. This mutation type was
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Table  1
Summary of TP53 mutation frequency and pattern detected in immortalised clones of Xpa-WT and Xpa-Null HUFs treated with 3-NBA.
3-NBA Xpa-WT Xpa-Null control Xpa-WT Xpa-Null
Total 3-NBA-treated HUF cultures (#) 60 60 Total 0.1% DMSO-treated HUF cultures (#) 54 54
TP53-mutant immortalised clones (#) 11 11 TP53-mutant immortalised clones (#) 2 2
Total  TP53 mutations detected (#) 14 12 Total TP53 mutations detected (#) 2 2
Frequency of TP53-mutant clones 18.3% (11/60) 18.3% (11/60) Frequency of TP53-mutant clones 3.7% (2/54) 3.7% (2/54)
Mutations on the transcribed strand 42.8% (6/14) 8.3% (1/12) Mutations on the transcribed strand 50% (1/2) 100% (2/2)
TP53  mutation pattern TP53 mutation pattern
G  to A 21.4% (3/14) 16.7% (2/12) G to A 0% (0/2) 0% (0/2)
G  to C 21.4% (3/14) 25% (3/12) G to C 50% (1/2) 0% (0/2)
G  to T 28.6% (4/14) 50% (6/12) G to T 0% (0/2) 0% (0/2)
A  to C 14.3% (2/14) 0% (0/12) A to C 50% (1/2) 100% (2/2)
A  to G 7.1% (1/14) 0% (0/12) A to G 0% (0/2) 0% (0/2)
A  to T 7.1% (1/14) 0% (0/12) A to T 0% (0/2) 0% (0/2)
Ins.  G 0% (0/14) 8.3% (1/12) Ins. G 0% (0/2) 0% (0/2)
TP53  mutation pattern at CpG sites TP53 mutation pattern at CpG sites
Total  G mutations at CpG 40% (4/10) 41.7% (5/12) Total G mutations at CpG 0% (0/1) 0% (0/0)
G  to A at CpG 66.7% (2/3) 0% (0/2) G to A at CpG 0% (0/0) 0% (0/0)
G  to C at CpG 0% (0/3) 33.3% (1/3) G to C at CpG 0% (0/1) 0% (0/0)
G  to T at CpG 50% (2/4) 66.7% (4/6) G to T at CpG 0% (0/0) 0% (0/0)
Ins.  G at CpG 0% (0/0) 0% (0/1) Ins. G at CpG 0% (0/0) 0% (0/0)
Fig. 4. TP53 mutation pattern and strand bias in 3-NBA-treated Xpa-WT and Xpa-Null HUFs. (A) The % of each type of single base substitution or insertion is shown. (B) The
number of each type of single base substitution or insertion occurring on the non-transcribed strand (NTS) or transcribed strand (TS) is shown.
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tot found in 3-NBA-treated Xpa-Null cultures, but was found in
 clones from 3-NBA-treated Xpa-WT HUFs (XW-3N-15 and -54;
able 2); notably, these clones also harboured a second TP53 muta-
ion.
.5.3. Mutational strand bias
As the non-transcribed strand of TP53 is repaired more slowly
han the transcribed strand in cells with normal NER capacity,
utations induced by carcinogens such as BaP or UV are preferen-
ially found on the non-transcribed strand [42,43]. In cells deﬁcientin TC-NER, however, an increase in mutations on the transcribed
strand may  occur [44]. Indeed, we previously showed that BPDE-
induced TP53 mutations were more frequently induced on the
transcribed strand in Xpa-Null HUFs compared with Xpa-WT HUFs
[27]. Interestingly, here we did not ﬁnd an excess of 3-NBA-induced
TP53 mutations on the transcribed strand in Xpa-Null HUFs (Table 2,
Fig. 4). In fact, only one Xpa-Null clone harboured a mutated gua-
nine on the transcribed strand (G:C > T:A at codon 273) compared
with ﬁve such mutations in Xpa-WT clones (G:C > T:A at codons 178
and 179; G:C > C:G at codon 161; G:C > A:T at codons 248 and 282).
28
 
J.E.
 K
ucab
 et
 al.
 /
 D
N
A
 R
epair
 39
 (2016)
 21–33
Table 2
TP53 mutations induced by 3-NBA in immortalised Xpa-WT and Xpa-Null HUFs.
Xpa status Treatmenta Clone Idb Codon # Exon Mutation type Strand WT codon MUT codon Coding change CpG Zygosity Contact, structure, zinc Activityc
TP53-mutated immortalised clones from HUFs treated with 1 M 3-NBA
WT  2 XW-3N-9 120 4 A:T > T:A NTS AAG ATG K120M Homo-/hemi- C NF
WT  1 XW-3N-59 158 5 G:C > T:A NTS CGC CTC R158L CpG Homo-/hemi- NF
WT  2 XW-3N-14 161 5 G:C > C:G NTS GCC CCC A161P Hetero- PF
WT  2 XW-3N-15 161 5 G:C > C:G TS GCC GGC A161G Hetero- PF
WT  1 XW-3N-55 175 5 G:C > T:A NTS CGC CTC R175L CpG Homo-/hemi- S PF
WT  1 XW-3N-54 178 5 G:C > T:A TS CAC CAA H178Q Hetero- NF
WT  2 XW-3N-8 179 5 G:C > T:A TS CAT AAT H179N Homo-/hemi- Z PF
WT  1 XW-3N-54 179 5 A:T > C:G NTS CAT CCT H179P Hetero- Z PF
WT  2 XW-3N-15 194 6 A:T > C:G TS CTT CGT L194R Hetero- NF
WT  2 XW-3N-7 236 7 A:T > G:C NTS TAC TGC Y236C Homo-/hemi- NF
WT  1 XW-3N-43 248 7 G:C > A:T TS CGG TGG R248W CpG Hetero- C NF
WT  2 XW-3N-14 249 7 G:C > C:G NTS AGG  AGC R249S Hetero- S NF
WT  1 XW-3N-37 282 8 G:C > A:T TS CGG TGG R282W CpG Homo-/hemi- S NF
WT  1 XW-3N-29 in. 3 (SA) G:C > A:T NTS Homo-/hemi- N/A
Null  1 XN-3N-151 124 4 insertion, G NTS TGC TG-G Frameshift Homo-/hemi- N/A
Null  2 XN-3N-117 157 5 G:C > T:A NTS GTC TTC V157F CpG Hetero- NF
Null  2 XN-3N-120 157 5 G:C > T:A NTS GTC TTC V157F CpG Hetero- NF
Null  1 XN-3N-137 244 7 G:C > C:G NTS GGC GCC G244A Hetero- NF
Null  1 XN-3N-136 245 7 G:C > C:G NTS GGC CGC G245R CpG Homo-/hemi- S NF
Null  1 XN-3N-137 249 7 G:C > C:G NTS AGG  ACG R249T Hetero- S NF
Null  1 XN-3N-156 273 8 G:C > T:A TS CGT AGT R273S CpG Hetero- C NF
Null  2 XN-3N-105 273 8 G:C > T:A NTS CGT CTT R273L CpG Hetero- C NF
Null  1 XN-3N-140 277 8 G:C > T:A NTS TGT TTT C277F Hetero- C NF
Null  1 XN-3N-141 277 8 G:C > A:T NTS TGT TAT C277Y Hetero- C NF
Null  2 XN-3N-110 in. 5 (SA) G:C > A:T NTS splice Homo-/hemi- N/A
Null  1 XN-3N-157 in. 8 (SA) G:C > T:A NTS splice Homo-/hemi- N/A
TP53-mutated  spontaneously immortalised clones from control HUFs (treated with 0.1% DMSO)d
WT  XW-C-115 138 5 G:C > C:G NTS GCC CCC A138P Homo-/hemi- NF
WT  XW-C-137 173 5 A:T > C:G TS GTG GGG V173G Homo-/hemi- NF
Null  XN-C-325 113 4 A:T > C:G TS TTC GTC F113V Homo-/hemi- NF
Null  XN-C-338 113 4 A:T > C:G TS TTC GTC F113V Hetero- NF
a Treatment refers to 1 or 2 × 48 h.
b XW = Xpa-WT; XN = Xpa-Null; 3N = 3-NBA- treated; C = control.
c The overall transactivation activity of the mutant in a yeast functional assay published by Kato et al. [46]. (NF = non-functional, PF = partially functional, F = functional, NA = not assessed).
d As published previously [27].
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Fig. 5. The spectrum of TP53 mutations induced by 3-NBA in Xpa-WT and Xpa-Null HUFs compared with mutations found in human tumours. Shown are (A) the number
of  mutations at each codon (within exons 4–9) in the TP53 gene induced by 3-NBA in HUFs compared with the frequency of mutation at each codon in (B) lung cancer of
smokers (exclusions: radon, asbestos, mustard gas, and coal [65,66], (C) lung cancer of non- and passive-smokers (exclusions: radon, asbestos, mustard gas, and coal [65,66]
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.5.4. Codon distribution and effect of mutations on p53 function
3-NBA-induced TP53 mutations occurred in all sequenced exons
4–9). Only one codon, 249, was mutated in both Xpa-WT and
pa-Null HUFs. In both cases the mutation type at codon 249 was
:C > C:G, although a different guanine was targeted in the Xpa-WT
nd Xpa-Null clones (AGG to ACG vs . AGG to AGC, respectively). Of
he seven residues in the p53 core DNA binding domain that make
irect contact with DNA bases (K120, S241, R248, R273, A276, C277,
280), two were mutated in Xpa-Null clones (R273 and C277) and
wo were mutated in Xpa-WT clones (K120 and R248) [45]. Addi-
ionally, several mutations were induced at residues that support
he structure of the DNA binding surface of p53: G245 and R249
n Xpa-Null clones; R175, R249 and R282 in Xpa-WT clones. H179, residue important for coordinating zinc-binding, was mutated in
wo Xpa-WT clones.ancer: IARC TP53 Mutation Database, R17 (November 2013). Mutation hotspots are
The majority of the 3-NBA-induced TP53 mutations were classi-
ﬁed as non-functional, based on a comprehensive study of mutant
transactivation function in yeast [46]; ﬁve mutations were clas-
siﬁed as partially functional. Three of the mutations with partial
functionality (A161P, A161G, H179P) were detected in clones har-
bouring two mutations (XW-3N-14, -15, 54), where the second
mutation was non-functional (R249S, L194R, and H178Q, respec-
tively). This suggests, as discussed previously [27], that the HIMA
selects for clones harbouring non-functional p53 mutants and that
p53 mutants retaining partial functionality may  not be capable of
senescence bypass.3.5.5. Comparison of 3-NBA-induced TP53 mutations with
mutations found in human cancer
The TP53 mutations induced by 3-NBA were compared with
TP53 mutations found in human cancer, as catalogued in the IARC
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Fig. 6. Mutant frequency at the lacZ locus in Xpa-WT and Xpa-Null HUFs treated
with 3-NBA. HUFs were treated for 48 h with the indicated concentrations of 3-NBA0 J.E. Kucab et al. / DN
P53 mutation database, version R17 (Fig. 5). The frequency of each
utation was assessed in lung cancer of smokers and non-smokers,
s well as cancer overall (Fig. 5B–D). Each mutation induced by 3-
BA in this study has been found in at least one human tumour.
urther, all codons and splice sites mutated by 3-NBA have been
argeted in lung tumours, including 16/25 identical mutations.
Interestingly, all of the most frequently mutated hotspot codons
n smokers’ lung cancer (157, 158, 175, 179, 245, 248, 249, 273,
82) or cancer overall (175, 245, 248, 249, 273, 282) were mutated
ollowing 3-NBA treatment in the HIMA (Fig. 5A). Six hotspots were
utated in Xpa-WT clones (158, 175, 179, 248, 249, 282) and four
otspots were mutated in Xpa-Null clones (157, 245, 249, 273). In
act, the mutation spectrum induced by 3-NBA in the current HIMA
losely mirrors that of smokers’ lung cancer (Fig. 5B).
Speciﬁc mutations induced by 3-NBA in this HIMA that are
ost frequently detected in human cancer include GTC to TTC
t codon 157, CGC to CTC at codon 158, and CGG to TGG at
odons 248 and 282 (Supplementary Table 4). Interestingly, those
our hotspot codons have never been reported as mutated in
pontaneously immortalised HUFs, suggesting that they may  rep-
esent speciﬁc targets for carcinogen-induced mutations. Further,
:C > A:T transversions located at codons 157, 158, 175, 273 and
77, all of which were induced by 3-NBA in this study, are more
ommonly found in lung cancer than in cancer overall. Therefore,
ne could speculate that these mutations in lung tumours may  indi-
ate exposure to compounds such as nitro-PAHs or PAHs found in
ir pollution or tobacco smoke.
.5.6. Comparison to mutations from previous HIMAs
The TP53 mutations induced by 3-NBA in the current study were
ompared to the mutations generated in previous HIMAs (Supple-
entary Table 5). Four codons (236, 244, 245, 273) mutated by
-NBA in the current assay were also targeted by 3-NBA in a pre-
ious assay [18]. Identical mutations at three codons occurred in
oth 3-NBA studies (236: TAC to TGC; 244: GGC to GCC; 273: CGT
o CTT). Further, identical mutations to those induced by 3-NBA at
ve codons in the current study were also induced by treatment
ith BaP/BPDE (157: GTC to TTC; 158: CGC to CTC; 245: GGC to
GC; 249: AGG to AGC; 273: CGT to AGT or CTT). While aristolochic
cid I (AAI) and UV also targeted several similar hotspot codons to
-NBA (AAI: 158, 179, 245, 249, 273; UV: 179, 248, 249) the muta-
ions induced at these sites by AAI and UV were not identical to
hose generated by 3-NBA.
.6. 3-NBA-induced mutation of lacZ reporter gene in Xpa-WT
nd Xpa-Null HUFs
The impact of NER deﬁciency on 3-NBA-induced mutagenesis in
UFs was further assessed at the lacZ reporter gene. The Xpa-WT
nd Xpa-Null HUFs utilised in this study harbour a pUR288 plasmid
ocus containing lacZ. Within a few days of treating HUFs with a
arcinogen, the pUR288 plasmid can be recovered from HUF DNA
nd ampliﬁed in E. coli to determine lacZ mutant frequencies.
Xpa-WT and Xpa-Null HUFs were treated with 0.1–2.0 M 3-
BA for 48 h, and then assessed for frequency of lacZ mutations
fter 4 days of mutation ﬁxation (Fig. 6). A background mutant
requency of 14–15 × 10−5 was detected in both Xpa-WT and Xpa-
ull HUFs. Following treatment with increasing concentrations of
-NBA, a dose-dependent increase in lacZ mutant frequency was
bserved. Interestingly, as found for TP53 in the HIMA, the mutant
requency of lacZ was very similar between Xpa-WT and Xpa-Null
UFs at all concentrations, with the exception of cells treated with M 3-NBA, where the lack of viable cells precluded the assess-
ent of mutants in Xpa-Null HUFs. Treatment with 1 M 3-NBA
ncreased the mutant frequency ∼6-fold over the background to
2 × 10−5 in Xpa-WT and Xpa-Null HUFs. The mutant frequency in(or 0.1% DMSO solvent control) and then allowed to proliferate for 4 days to ﬁx DNA
damage into mutations. LacZ mutant frequencies were calculated as the number of
mutant colonies per number of recovered transformants.
Xpa-WT HUFs rose to ∼9-fold over background (133 × 10−5) fol-
lowing treatment with 2 M 3-NBA.
4. Discussion
In this study, TP53 and lacZ mutagenesis by the carcinogenic air
pollutant 3-NBA was assessed in Xpa-WT and Xpa-Null HUFs. As
Xpa is required for the removal of bulky adducts from the DNA by
NER, it was  hypothesised that greater persistence of 3-NBA-DNA
adducts in Xpa-Null HUFs would lead to increased mutation fre-
quency. However, a similar frequency of 3-NBA-induced TP53 and
lacZ mutations was  detected in Xpa-WT and Xpa-Null HUFs.
Xpa-Null HUFs and Hupki mice were much more sensitive to
3-NBA than their Xpa-WT counterparts. A pronounced decrease
in survival was observed for Xpa-Null HUFs treated with the
highest concentrations of 3-NBA and Xpa-Null Hupki mice died
within 2–3 days of receiving 2 mg/kg bw 3-NBA. A similar response
was found previously for Xpa-Null HUFs and Hupki mice treated
with BaP [27]. Further, this sensitivity to genotoxicants was  also
shown for Xpa-Null mice with wild-type Trp53 after exposure to
UV or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
[33,47]. While Xpa-Null and Csb (Cockayne syndrome B)-Null cells,
both deﬁcient in TC-NER, undergo apoptosis after DNA damage
induced by UV or BaP, Xpc-Null cells or mice, deﬁcient only in
GG-NER, do not [48,49]. The inability of TC-NER-deﬁcient cells to
remove DNA lesions from the transcribed strand of active genes is
a strong trigger for the induction of apoptosis [50]. Lesions that
persist on the transcribed strand can block the progression of
RNAPII transcription complexes, which may  subsequently collide
with DNA replication forks during S-phase [51]. Therefore, the sen-
sitivity of Xpa-Null HUFs and Hupki mice to 3-NBA could be due
to the blocking of RNAPII progression by 3-NBA-DNA adducts. In
this context it is noteworthy that a recent study found that 3-NBA-
DNA adducts markedly block DNA replication [52]. The replication
frequency of dG-C8-N-3-ABA was  ∼17% compared with ∼33% for
dG-N2-3-ABA and ∼43% for dA-N6-3-ABA [52].
Despite increased sensitivity to 3-NBA, Xpa-WT and Xpa-Null
HUFs accumulated similar 3-NBA-DNA adduct levels. Further, 24 h
after a single administration of 3-NBA, a difference in 3-NBA-DNA
adduct formation between Xpa-WT and Xpa-Null Hupki mice was
only observed in the lung (see Fig. 1). Previously, DNA adduct levels
induced by BaP were found to be higher in several tissues (spleen,
colon, kidney) in Xpa-Null relative to Xpa-WT Hupki mice [27].
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hese results indicate that repair of bulky DNA adducts may  be
issue- and lesion-speciﬁc.
The fact that Xpa-Null HUFs did not exhibit an increase in
-NBA-induced mutation frequency at the TP53 and lacZ loci
or an increase in DNA adduct levels, compared to Xpa-WT
UFs, suggests that, contrary to expectation, 3-NBA-derived DNA
dducts may  not be recognised and repaired by GG-NER. GG-NER
s initiated following damage recognition by XPC/hHR23B and
ay  occur with varying efﬁciency, depending on the structure and
equence context of the lesion [53]. Recognition of bulky adducts
y XPC/hHR23B is correlated with the degree of thermodynamic
estabilisation induced by the lesion [54,55]. Lesions that dis-
ort and destabilise the DNA helix locally (e.g. pyrimidine (6–4)
yrimidone photoproducts [6-4PPs] or 10-(deoxyguanosin-
2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene
dG-N2-BPDE]) are repaired efﬁciently by GG-NER [56,57],
hereas lesions that distort DNA to a lesser degree (e.g. cyclobu-
ane pyrimidine dimers [CPDs]) or that stabilise DNA (e.g.
-(deoxyguanosin-N2-yl)-2-acetylaminoﬂuorene [dG-N2-AAF]
r 8,9-dihydro-8-(2,6-diamino-4-oxo-3,4-dihydropyrimid5-yl-
ormamido)-9-hydroxyaﬂatoxin B1 [AFB1-FAPY]) are repaired less
fﬁciently [58,59].
It was recently shown that the major DNA adduct formed after
etabolic activation of 3-NBA, dG-N2-3-ABA, had a stabilising
ffect when incorporated into a synthetic oligonucleotide [60]. The
G-N2-3-ABA adduct-containing duplex formed a regular double
elical structure, with the adduct residing in the minor groove.
herefore, it is possible that the thermodynamic stability of dG-
2-3-ABA, which is the most abundant and persistent 3-NBA-DNA
dduct formed in vivo [61], may  indeed prevent its recognition
nd removal by GG-NER. It is important to consider, however, that
etabolic activation of 3-NBA generates 4 major adducts, includ-
ng dG-N2-3-ABA (see Supplementary Fig. 1) with ∼80% of adducts
ccurring at deoxyguanosine and ∼20% at deoxyadenosine [9,11];
he thermodynamic stability of the other moieties is unknown.
 recent study evaluating the formation and removal of dA-N6-
-ABA, dG-N2-3-ABA and dG-C8-N-3-ABA in human cells found
hat dA-N6-3-ABA and dG-C8-N-3-ABA were repaired more efﬁ-
iently than dG-N2-3-ABA [52]. After a 24-hour period ∼85% of the
G-N2-3-ABA adducts remained, whereas only ∼50% of the dG-C8-
-3-ABA adducts and ∼40% of dA-N6-3-ABA adducts were present
n the cells [52].
In contrast to our ﬁndings, however, are the results of an earlier
tudy where a supF shuttle vector plasmid was treated with N-
co-3-ABA, a reactive metabolite of 3-NBA, and then propagated in
ER-proﬁcient and -deﬁcient human ﬁbroblasts (WI-38-VA13 and
P2OS(SV), respectively) [16]. Nearly 2-fold more supF mutations
ere induced in plasmids recovered from the XP2OS(SV) cells com-
ared with the WI-38-VA13 cells. Using a polymerase stop assay,
he authors determined that 92% of the N-Aco-3-ABA-induced DNA
dducts were located at G:C base pairs in supF. DNA adducts were
ot measured in this study, however, therefore their exact compo-
ition, such as the proportion of dG-N2-3-ABA adducts, is unknown.
nterestingly, a higher frequency of supF mutations induced in the
P2OS(SV) cells occurred at A:T base pairs, compared with the NER-
roﬁcient cell line (34% versus 17%, respectively) [16]. The authors
oncluded that dA-3-ABA adducts may  be more readily recognised
y NER than dG-3-ABA adducts, leading to an increase in mutations
t A:T sites in NER-deﬁcient cells. However, this was  not the case for
P53 mutations induced by 3-NBA in Xpa-Null HUFs. While ∼30%
f the 3-NBA-induced TP53 mutations in Xpa-WT HUFs occurred at
:T base pairs, all of the mutations in Xpa-Null HUFs occurred at
:C base pairs.
There are several possible explanations for the differences
etween our ﬁndings and those of Nishida et al. [16]. Firstly, the
upF gene is not transcribed in human cells, therefore dA-3-ABAir 39 (2016) 21–33 31
adducts in supF would not cause RNAPII blockage or apoptosis in
XP2OS(SV) cells, but could instead induce mutations. Further, the
relative proportion of individual 3-NBA-derived DNA adducts in our
systems may  be different. The adducts detected in the present study
were generated following enzymatic activation of 3-NBA in HUFs,
whereas the supF shuttle vector was directly reacted with N-Aco-3-
ABA in situ prior to cell transfection. As discussed above, DNA  repair
efﬁciency of the four major 3-NBA-derived DNA adducts varies [52],
ultimately inﬂuencing mutagenesis. Additionally, it could be that
3-NBA-derived DNA adducts are recognised and repaired differ-
ently in human cells and mouse cells, or that GG-NER of adducts
contained on plasmids operates differently to GG-NER of adducted
genomic DNA.
Most 3-NBA-induced mutations occurred at G:C base pairs, with
G:C > T:A transversions the predominant mutation type in both
Xpa-WT and Xpa-Null HUFs. This is in agreement with the results
of an earlier HIMA using 3-NBA performed by vom Brocke et al.
[18]. Of note, the dG-N2-3-ABA and dG-C8-N-3-ABA adducts are the
predominant 3-NBA-DNA adducts formed in HUFs and both lesions
have recently been shown to induce G:C > T:A transversions in site-
speciﬁc mutagenesis assays in human cells [52]. Four codons were
targeted by 3-NBA in both our study and that of vom Brocke et al.
(236, 244, 245, 273) [18]. We  found that 32% (8/25) of unique TP53
mutations occurred at CpG sites, compared with only 14% (3/22) in
the previous HIMA using 3-NBA. Interestingly, we also found that
all of the CpG sites targeted by 3-NBA are hotspots for mutation in
human cancer, including smokers’ lung cancer (i.e. codons 157, 158,
175, 245, 248, 273, 282). Carcinogens such as BPDE show enhanced
adduct formation at many of these sites (codons 157, 158, 245, 248,
273) [62,63]. Our results suggest that metabolites of 3-NBA may
also exhibit preferential binding at such sites, although this would
have to be conﬁrmed in future studies. The existence of mutation
hotspots in cancer can also be inﬂuenced by other factors besides
enhanced carcinogen binding. These sites may  be more resistant to
repair or may  be more readily bypassed by error-prone translesion
polymerases. Additionally, it is possible that these mutations are
highly selected for due to their deleterious impact on the function
of p53 or their gain-of-function properties [20]. Nevertheless, the
spectrum of mutations generated in this study indicates that sim-
ilar factors inﬂuence TP53 mutagenesis in the HIMA and human
cancer.
For the ﬁrst time, we  were able to assess mutagenesis at a lacZ
reporter gene in HUFs in addition to TP53 mutagenesis. This allowed
us to compare the frequency of 3-NBA-induced TP53 mutations,
detected following a several-month selection process in mam-
malian cells, to the frequency of lacZ mutations generated, but not
subjected to selection, in the same cells. In future studies having
lacZ integrated into HUFs could aid in the optimisation of car-
cinogen treatment conditions, where the mutagenic activity of an
agent could be determined at the lacZ locus prior to initiating the
more laborious HIMA. The data generated in the present study,
comparing 3-NBA-induced mutagenesis of TP53 and lacZ in HUFs,
may  serve as an initial point of reference for identifying a level of
lacZ mutation frequency in primary HUFs commensurate with TP53
mutation frequency in immortalised clones.
While a lack of recognition of 3-NBA-DNA adducts by GG-NER
could explain why TP53 mutant frequency was  not increased in
Xpa-Null HUFs, as discussed above, it is unclear why  these cells
did not at least harbour more mutations on the transcribed strand
compared with Xpa-WT HUFs, as was  observed previously for BPDE
[27]. It will be important to examine additional mutagens in future
studies, particularly those with ﬁrm evidence for removal by NER
(e.g. UV). One drawback of using Xpa-Null HUFs in the HIMA is
their extreme sensitivity to genotoxicants that block RNAPII. This
sensitivity necessitates treating Xpa-Null HUFs with a much lower
concentration of carcinogen than Xpa-WT cells can tolerate, and
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herefore lowers the level of premutagenic DNA damage. Xpa-Null
UFs may  be particularly useful for improving HIMA mutation fre-
uencies when assessing mutagens that do not generate high levels
f DNA damage in HUFs, if such damage is recognised by GG-NER.
urthermore, Xpa-Null HUFs may  be useful in determining the role
ER plays in shaping TP53 mutagenesis, rather than simply increas-
ng mutation frequencies.
Although NER-deﬁcient HUFs did not increase the frequency
f 3-NBA-induced mutations in the HIMA, data from this study
ontribute to our understanding of the TP53 mutation spectrum
nduced by 3-NBA and further indicate that 3-NBA-derived DNA
dducts may  evade removal by GG-NER. The persistence of 3-NBA
dducts in DNA may  be an important factor in its mutagenicity
9,52,61]. 3-NBA is an air pollutant, predominantly originating from
iesel emissions [2,6]. Occupational diesel exhaust exposure has
een shown to increase the risk of developing lung cancer [2,64],
nd compounds such as 3-NBA may  contribute to the process. The
urrent evidence from experimental models indicates that 3-NBA
s a potent mutagen and carcinogen, but it will be important to
ssess TP53 mutations in tumour samples from diesel exhaust-
xposed individuals in order to assess more fully what impact this
ompound has on human carcinogenesis.
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